Antibody-drug conjugates (ADCs) are combinations of a monoclonal antibody and a cytotoxic drug and have been used in many instances to treat other tumors: trastuzumab emtansine for metastatic HER2 + BC, and brentuximab vedotin for the treatment of recurrent Hodgkin lymphoma and anaplastic large cell lymphoma [41,42,43]. Here, ERBB2 is linked to breast cancer.